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lipoprotein cholesterol, such as alirocumab, require administration by
subcutaneous injections. There is a need to assess the acceptance of
such treatments and their mode of administration. Objectives: To
develop a novel patient-reported outcome measure, the Injection-
Treatment Acceptance Questionnaire (I-TAQ), and assess its content
validity using qualitative methods. Methods: Concepts generated
from a literature and instrument review informed the initial drafting
of 17 items in the I-TAQ, with item wording adapted from three
existing instruments. Three rounds of qualitative interviews were
conducted with 29 US-English speaking patients at high cardiovascu-
lar risk. Concept elicitation questioning was used to explore patients’
treatment experiences followed by cognitive debrieﬁng of the
I-TAQ using “think-aloud” methods. Verbatim transcripts were ana-
lyzed using thematic analysis. Results: Qualitative analysis of
concept elicitation data identiﬁed the following relevant concepts:
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ndence to: Sophi Tatlock, Adelphi Values, Adelphiacceptance. Seven (24%) patients discussed an initial fear of needles,
but described this as subsiding with no impact on adherence. Five items
were added after round one interviews, three of which were retained
after round two testing in which two further items were added, forming
the conceptually comprehensive 22-item I-TAQ. Patients demonstrated
good understanding of item wording, instructions, response scales, and
recall period. Conclusions: Successive rounds of in-depth interviews
resulted in a treatment acceptance measure with strong content
validity. Pending demonstration of its psychometric properties, the
I-TAQ may prove to be a valuable measure of patients’ perspectives
toward being treated with low-density lipoprotein cholesterol–lowering
therapies requiring subcutaneous injections.
Keywords: acceptance, instrument development, patient-reported
outcome, qualitative research.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Elevated low-density lipoprotein cholesterol (LDL-C) levels are
associated with an increase in the risk of cardiovascular (CV)
events, including myocardial infarction, unstable angina, need
for coronary revascularization procedures, ischemic stroke, and
death. Evidence from numerous randomized clinical trials have
demonstrated that LDL-C reduction, via statin- and non–statin-
based therapies, leads to a reduction in CV events [1–5]. Recently,
treatment with monoclonal antibodies to proprotein convertase
subtilisin–kexin type 9, such as alirocumab, has been shown to
reduce LDL-C levels in phase 3 studies with populations at
moderate to very high levels of baseline CV risk who are being
treated with statins or are unable to tolerate statins [6,7]. Thesetherapies are being further tested for their impact on reducing CV
outcomes [8]. These agents, however, require patients to self-
administer the medication with subcutaneous injections, a treat-
ment strategy that has seldom been used in the management of
CV disease. Given the novelty of this treatment strategy, under-
standing patients’ perspectives about using injection treatments,
as opposed to oral medications, is important, but difﬁcult to
quantify with existing measures.
The aim of this work was to develop a patient-reported
outcome (PRO) to assess patients’ acceptance of a subcutaneous
injection treatment for lowering LDL-C in a high CV risk pop-
ulation, following the Food and Drug Administration patient-
reported outcome guidance as a framework [9]. A literature
review, followed by three rounds of patient interviews, wasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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drafted measure, the Injection-Treatment Acceptance Question-
naire (I-TAQ).Methods
Drafting of the I-TAQ
The ﬁrst conceptual step was to consider whether it would be
more appropriate to assess patient “satisfaction” or “acceptance”
toward an injection treatment for an asymptomatic condition as
both concepts have been used in previous studies of populations
receiving injectable treatments [10,11]. Given the asymptomatic
nature of hypercholesterolemia, it was felt to be more appropri-
ate and relevant to assess whether patients are willing to
“accept” taking their injection treatment, as opposed to asking
patients how “satisﬁed” they are with having to inject a
treatment.
After deﬁning the overall measurement concept the concep-
tual domains of the Health Belief Model were used as a frame-
work for developing the I-TAQ, including perceived severity,
perceived susceptibility, perceived beneﬁts, perceived barriers,
modifying variables, cues to action, and self-efﬁcacy [12]. In
addition, ﬁve existing PRO instruments of greatest relevance
were identiﬁed from the literature and reviewed in detail: the
Treatment Satisfaction Questionnaire for Medication (TSQM) [13],
the Treatment Satisfaction with Medication Questionnaire
(SATMED-Q) [14], the Preference and Satisfaction Questionnaire
(PSQ) [15], the Self-Injection Assessment Questionnaire (SIAQ)
[16], and the Acceptance by the Patients of their Chronic Treat-
ment Acceptance Questionnaire (ACCEPT) [17]. The instruments,
however, were not deemed to have appropriate content validity
for this population as none was adequately focused on assessing
treatment acceptance speciﬁcally in relation to injection treatments.
Therefore, it was felt that patients’ concerns or experiences
related to this treatment modality might not be adequately
captured. In addition, the unique nature of elevated LDL-C level
as a “silent” condition warranted a renewed effort to understand
patients’ perspectives of using subcutaneous injection therapies.
Initial items were therefore drafted to capture relevant concepts
identiﬁed from the literature and existing instruments and
within the constructs articulated in the Health Belief Model.
Qualitative Study Design
A non-interventional qualitative study was conducted with 29
US-English speaking patients at high CV risk who had experience
of self-administering their treatment for lowering LDL-C every
2 weeks via subcutaneous injection. Qualitative face-to-face
interviews were conducted in three rounds (n ¼ 9, n ¼ 10, and
n ¼ 10 patients in each round, respectively) by trained inter-
viewers and were audio recorded. The ﬁrst two rounds involved
patients who had self-administered their treatment with pre-
ﬁlled pens (PFPs; n ¼ 19), and the last round involved patients
who had self-administered their treatment with pre-ﬁlled
syringes (PFSs; n ¼ 10). Interim analysis was performed after
each round of interviews to enable consideration of additional
items and subsequent testing of revisions. The ﬁrst part of each
interview, conducted before the patient had been shown the
questionnaire, focused on concept elicitation. The second part
focused on cognitive debrieﬁng of the I-TAQ.
Patient recruitment
All participants were recruited through purposeful sampling from
either a randomized double-blind, placebo-controlled clinical
trial or an open-label extension trial for alirocumab. Inclusioncriteria for the interview study required all patients to have been
diagnosed with elevated LDL-C, be 18 years of age or older, and
have experience of self-administering alirocumab or placebo via
PFP or PFS. Quotas relating to diagnosis (heterozygous familial
hypercholesterolemia, high or very high CV risk), treatment,
ethnicity, and education were used to recruit a sample with a
broad range of clinical and demographic characteristics. Catego-
rization of high and very high CV risk was based on the National
Cholesterol Education Program Adult Treatment Panel III guide-
lines [18].
Concept elicitation
To support the capture of a broad range of concepts articulated in
the Health Belief Model, an interview guide was constructed
containing a number of broad, open-ended, and non-leading
questions to guide the interviewer (see Appendix 1 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2015.09.
2937). The questions were designed to encourage patients to
describe their experiences using their own language and to
prohibit any possible bias. The discussions were exploratory
and focused on eliciting spontaneous comments from patients
regarding their treatment experience and the factors that (pos-
itively or negatively) affected their treatment acceptance and
adherence. If the patients did not spontaneously mention a
concept of interest identiﬁed from the literature in response to
the broad questioning, more direct questions were used to
explore that concept toward the end of the interview. In addition,
the relevance of the concepts 'satisfaction' and 'acceptance' was
explored with patients in terms of how they described their
treatment experience.
Cognitive debrieﬁng
After the concept elicitation (CE) section of the interview, cogni-
tive debrieﬁng (CD) was performed. Patients were asked to
complete the I-TAQ using a “think-aloud” approach, requiring
the patients to read each instruction, question, response option,
and recall period out loud while verbally sharing their reasoning
for selecting each response [19,20]. Patients were also asked
detailed debrieﬁng questions about their understanding of terms
and response scale wording, relevance of concepts, and appro-
priateness of the response options and the recall period. More
time was spent on the CE part of the interview in round one to
ensure all relevant and important concepts were captured. As
saturation was achieved, more time was spent on thoroughly
debrieﬁng the I-TAQ, and revisions made following interim
analysis, in the subsequent interviews.
Ethics
The study was conducted in accordance with the Declaration of
Helsinki and approved and overseen by a centralized independent
review board in the United States (reference: ADEL-13-347). Writ-
ten informed consent was obtained from all participants before
the collection of any data and before any study-related activities.
Qualitative Analysis
All interviews were transcribed verbatim with all identiﬁable
information removed to protect anonymity of the patients.
Thematic analysis of the verbatim transcripts was performed
using computer-assisted qualitative data analysis software,
ATLAS.Ti [21], and each transcript was quality assessed, coded,
and analyzed by the researchers. Using an inductive approach, a
code list was created and adapted as new codes were added [22].
Patient quotes were grouped by code/theme to enable ﬁndings to
be summarized and conclusions drawn. Saturation of concepts
was evaluated for the CE results, deﬁned as the point at which no
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further interviews [23]. The CD transcripts were analyzed to
evaluate patients’ comprehension, interpretation, and perceived
relevance of items as well as the appropriateness of response
options and recall period of the I-TAQ.Results
Demographic and Clinical Characteristics
Key demographic and clinical information for the qualitative
sample is presented in Table 1. In total, 29 patients with high
CV risk (n ¼ 10), very high CV risk (n ¼ 9), and heterozygous
familial hypercholesterolemia (n ¼ 10) participated in the study,
19 of whom self-administered their treatment using a PFP and 10
of whom self-administered using a PFS. A broad age range of
participants was achieved (50–77 years), two-thirds of whom
were men (n ¼ 20 [69%]). Patients had a range of highest
education levels, from some high school (n ¼ 4 [14%]) to graduate
degree (n ¼ 3 [10%]). There was minimal diversity in ethnicity or
race as all but one of the patients were white (n ¼ 28 [97%]). All
patients (with the exception of one (n=28 [97%])), regardless of
their speciﬁc diagnosis, had been self-administering alirocumabTable 1 – Key clinical and demographic information
for the qualitative sample (N ¼ 29).
Summary characteristic Value
Age (y)
Mean 60.9
Range 50–77
Sex, n (%)
Female 9 (31.0)
Male 20 (69.0)
Mode of administration, n (%)
PFP 19 (66.5)
PFS 10 (34.5)
CV risk categorization, n (%)*
Heterozygous familial hypercholesterolemia 10 (34.5)
Very high risk of cardiovascular events 9 (31.0)
High risk of cardiovascular events 10 (34.5)
Duration of the diagnosis of CV risk condition, n (%)
4–7 years ago (2010–2006) 10 (34.5)
8þ years ago (r2005) 19 (65.5)
Duration of treatment with alirocumab, n (%)
1–6 months 1 (3.5)
7–11 months 15 (51.7)
12þ months 13 (44.8)
Background lipid-lowering medications n (%)
High-potency statin 15 (51.7)
Other statins 4 (13.8)
Ezetimibe 2 (10.4)
Niacin, ﬁbrate, bile acid sequestrant 4 (13.8)
Comorbid condition, n (%)
Hypertension 15 (51.7)
Type II diabetes 4 (13.8)
Coronary artery disease 4 (13.8)
Rheumatoid arthritis 1 (3.4)
Prior myocardial infarction 2 (6.9)
Peripheral vascular disease 1 (3.4)
CV, cardiovascular; PFP, preﬁlled pen; PFS, preﬁlled syringe.
* As reported by the referring clinicians. Categorization of very
high and high risk was based on the National Cholesterol
Education Program Adult Treatment Panel III guidelines [18].for at least 7 months. A large proportion of the sample had
comorbid conditions, with hypertension being the most common,
experienced by more than half of the sample (n ¼ 15 [51.7%]). In
addition, more than half of the sample were also taking a high-
potency statin (n ¼ 15 [51.7%]). All patients were recruited from
sites based in the United States.
CE Findings
Concepts of treatment acceptance
Key themes that emerged from the CE interviews included
perceived efﬁcacy of the treatment, acceptance of side effects,
injection self-efﬁcacy, injection convenience, and overall accept-
ance. Table 2 summarizes the number of patients who reported
each concept (either spontaneously, in response to an open-
ended question, or in response to a direct probe) with example
quotes.
Self-Efﬁcacy in administering the Injection. When probed,
patients described self-efﬁcacy in terms of conﬁdence in their
ability to administer the injection treatment. All patients (n ¼ 29
[100%]) described high levels of conﬁdence and reported feeling
“100% conﬁdent” (02-02), describing administering the injection
as “second nature” (03-09). Although most patients when asked
(n ¼ 15 of 20 [75%]) recalled experiencing apprehension when
administering their ﬁrst injection (seven of whom had a previous
fear of needles), all reported feeling conﬁdent in administering
their most recent injection. Similarly, seven patients (24%)
reported an initial fear of needles that subsided as experience
in administering the treatment was gained.
Nervous – and once I did it, uh, I realized that it’s not that
hard. It was very simple. (03-04)
Most patients (n ¼ 23 [79%]) did not report the injection to
have any impact on their psychological/emotional well-being.
Feeling scared of the needle (n ¼ 1 [3%]) and stress associated
with remembering when to take the injection were both men-
tioned as negative effects (n ¼ 1 [3%]). Four patients (13%)
reported a positive change in their psychological well-being after
the treatment due to the improvements in test results.
Perceived efﬁcacy of the treatment. Perceived efﬁcacy of the
treatment was deﬁned as the patient’s belief that the treatment
was effectively treating their condition. Most of the patients
interviewed (n ¼ 19 [66%]) did not know whether the treatment
was working because they had not seen their LDL-C levels; such
patients, therefore, relied on a belief as to whether or not their
treatment was effective. Patients recruited from the open-label
study had access to their results and therefore had knowledge of
their LDL-C levels as an indicator of efﬁcacy. Perceived efﬁcacy of
the treatment was reported to substantially inﬂuence patients’
acceptance and attitudes toward long-term use and adherence.
Injection convenience. The patients discussed how convenient
they found administering the injection, speciﬁcally by discussing
practical aspects such as the scheduling and frequency of doses,
remembering doses, managing missed doses, storage of the treat-
ment, and the time taken to prepare and administer the treatment.
Almost all patients (n ¼ 27 [93%]) found it easy to ﬁt the
injection into their schedule, comparing it to other routine
activities of daily living such as “brushing my teeth” (01-07). All
patients (n ¼ 29 [100%]) took the injection at home and reported
this to be the most convenient place to administer the treatment,
the majority of whom (n ¼ 21 [72%]) spontaneously reported
using a reminder to help them take their injection at the correct
time (e.g., setting a timer). In addition, 13 patients (45%) had
Table 2 – Counts of concepts and example quotes elicited through CE in qualitative interviews (N ¼ 29).
Concept Subconcept Spontaneous Probed Example quote
Self-efﬁcacy Self-efﬁcacy in
administering the
treatment
0 29 “Conﬁdent. You know, done it enough times now.
It’s…second nature now.” (03-09)
Perceived efﬁcacy of
the treatment
Perceived efﬁcacy of the
treatment
8 21 “I feel it’s helping my cholesterol.” (02-04)
Injection
convenience
Use of reminder 21 0 “I’ve got a calendar thing. And it’s written on there
when I do it.” (01-04)
Overall convenience 19 10 “It was convenient. Um, bec – again, because it ﬁt into
my... day without any big, uh – big issues.” (01-06)
Ease of use 17 12 “It’s real easy. Once you place it against your skin and
that, you press down on a little lever. And it stays
in until the injector’s empty. It pops back up, you
know, you’re done.” (01-03)
Injection site 20 9 “You can do your arm or your leg or whatever, but I
always do abdomen.” (03-11)
Preparation 9 1 “Use an alcohol swab – on the injection site. And then
I inject myself.” (03-10)
Storage 9 20 “The drug needs to be stored in a refrigerator. And so,
if you’re on vacation or something you need to stay
somewhere where there’s a refrigerator.” (01-02)
Frequency 6 23 “Once every two weeks, it’s easy.” (03-10)
Scheduling 6 22 “it’s easy. It’s like ﬂossing my teeth and brushing my
teeth in the morning, you kind of just ﬁt it in.”
(01-07)
Missed dose 6 14 “I travel a lot – and so I missed one of the windows
one time. I took it when I got back. I think I was two
or three days late or something… they said if I
missed the date, to go ahead and take it when –
when I could.” (01-06)
Time to administer 0 10 “Probably less than 15 minutes because I – after I take
it out of the refrigerator, I let it, you know, warm up
to room temperature.” (03-07)
Impact on daily life 0 29 “Well,…it doesn’t take any time (laughter) It doesn’t
affect anything I do.” (01-01)
Side effects Presence of side effects 12 13 “Sometimes just like a little…raised area in the skin,
but, you know, that goes away.” (01-05)
Impact on psychological/
emotional well-being
0 29 “Well, I would say positive…because it makes me feel
like maybe it’s given me a few more years on to my
life.” (03-02)
Pain 4 1 “The pain portion of it is when you’re positioning the
needle on your skin and then working it through
and poking it through. It’s just a bit of a pinprick
sensation, you know.” (03-10)
Overall acceptance Overall acceptance 0 29 “Very acceptable for me. It’s…painless and it’s quick.”
(01-01)
Acceptance of treatment
in addition to existing
treatments
0 27 “It’s easier because I only have to do it every two
weeks. So there’s less pills laying around and less
to remember.” (01-02)
Other Previous fear of needles 3 4 “Most of my life, I’ve kind of had a problem with, you
know, getting shots or needles or injections or
whatever. And I was really – had a lot of
reservations about this. It ended up not being a
problem whatsoever.” (03-11)
CE, concept elicitation.
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correct day. One patient felt neutral about the scheduling, “It
wasn’t easy or difﬁcult” (02-02), and one patient reported difﬁ-
culty remembering the injection due to a busy schedule, “Uh, one
time I was two days late because I forgot” (01-03).All patients reported storing the injection treatment in
the refrigerator, as instructed. Most patients (n ¼ 21 [72%])
found it easy to store the injection, whereas ﬁve (17%) reported
some elements of bother with storage, speciﬁcally while on
vacation.
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effects and side effects speciﬁc to the injection site (e.g., bruising
and swelling). Approximately half of the patients (n ¼ 15 [52%])
reported experiencing some kind of injection site–speciﬁc side
effect, such as a “prick,” “sting,” or “drop of blood,” but no effects
or bother was reported. The patients using the PFS reported more
site-speciﬁc side effects, such as bruising, stinging, and swelling,
than did patients using the PFP, but were not bothersome.
Notably, no side effects were reported to affect adherence,
persistence, or discontinuation.
Only ﬁve patients reported pain associated with injecting
(three spontaneously, two when probed); all ﬁve described pain
as minimal, brief, and of no burden. One of the ﬁve patients
reported a little pain at ﬁrst followed by saying that it was
painless:
Little bit painful from the point of view of, uh, when you
position the needle – on the outside of your skin – there’s a
little bit of like a – a pinprick type feeling, you know. After I
pop the, uh, needle through the skin, it’s painless. (03-10)
Similar to the lack of bother associated with side effects,
patients did not report any negative impact of the injection on
their daily activities or physical functioning.
Overall acceptance. All patients (100%) described the injection to
be an acceptable form of treatment overall, describing it as “100%
acceptable” and “no big deal.” Because of the high proportion of
patients with comorbidities, it was important to explore patients’
experience of administering the injection in addition to their
existing treatments/medications. All patients who administered
their injection in conjunction with other regular treatments (n ¼
27 [93%]) found the injection treatment to be an acceptable
addition to their treatment regime.
Treatment satisfaction and treatment acceptance
As part of CE, approximately half of the patients (n ¼ 14 [48%])
were asked to discuss the relevance of the terms “treatment
acceptance” and “treatment satisfaction” in describing their
injection-treatment experience. Five patients (36%) preferred
the term treatment acceptance, two (14%) preferred treatment
satisfaction, ﬁve (36%) did not have a preference, and two (14%)
felt that it was inappropriate to compare the two concepts.
Findings indicated patients interpreted acceptance as a concept
associated with willingness due to necessity.
Accepting means that you – you’re willing to work with
it. You’re willing to take it on and do what has to be done.
(02-04)
Given the asymptomatic nature of the condition and the fact
that the beneﬁt of treatment is in terms of reducing long-term
risk of CV events, rather than alleviating symptoms, it was
concluded that acceptance would be a more appropriate and
relevant concept to measure in assessing the patient experience
of self-administering a subcutaneous injection treatment.
Item Generation
The I-TAQ was developed as a paper-based PRO designed to
assess patient acceptance of an injectable treatment. All items
used a ﬁve-point response scale, with response options ranging
from “not at all conﬁdent” to “very conﬁdent,” “very unaccept-
able” to “very acceptable,” “not at all effective” to “very effective,”
“very difﬁcult” to “very easy,” “very inconvenient” to “very
convenient,” “deﬁnitely not” to “yes deﬁnitely,” and “not at all”
to “yes, very much.” The initial I-TAQ had 17 items grouped into
four domains: acceptance of perceived efﬁcacy (n ¼ 2 items),acceptance of side effects (n ¼ 5 items), acceptance of admin-
istration (n ¼ 7 items), and overall acceptance (n ¼ 3 items). The
conceptual framework was revised after each round of interviews
and the domain of injection self-efﬁcacy was added, resulting in a
ﬁnal ﬁve-domain framework (Fig. 1). All revisions to items and
detailed rationales for each decision are presented in Appendix 2
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.09.2937.
Cognitive Debrieﬁng Findings
Overall, all items in the I-TAQ were well understood and reported
to be relevant to patients. Minor revisions to items were incorpo-
rated, however, after each round of patient interviews on the
basis of patient feedback to enhance relevance and content
validity. Figure 2 provides an overview of the changes made to
the I-TAQ in each round.
Cognitive debrieﬁng of instructions and recall period
The instructions provided at the top of the I-TAQ ask patients to
think speciﬁcally about the injection treatment when selecting a
response and were well understood by most of the patients (n ¼
25 [86%]). Most of the patients across all rounds (n ¼ 27 [93%])
understood the recall period, but only 28% (n ¼ 8) of the patients
reported actually using the 4-week recall period when completing
the questionnaire. To aid consistent reporting, “over the past four
weeks” was included in every item to encourage patients to use
the correct recall period.
Revisions after round 1 interviews with patients using the PFP
(n ¼ 9). After the ﬁrst round of patient interviews (n ¼ 9), 5 items
were added to the original 17-item I-TAQ to further explore
understanding, relevance, and, in some cases, alternative item
wording for the assessment of a given concept. Speciﬁcally, items
capturing injection site reactions, self-efﬁcacy, time to administer
the injection, and overall acceptance were added for testing in
round 2.
Despite patients describing injection site reactions during CE,
only one patient completed side effects items during CD. There-
fore, an item asking speciﬁcally about injection site reactions was
added in addition to a general side effects item to ensure the
experience was fully captured. Because of being reported in CE, a
self-efﬁcacy item measuring the level of self-belief/conﬁdence in
ability to self-administer the injection treatment was added for
testing in round 2.
When discussing the time taken to administer the injection,
several patients talked about the time taken to prepare the
injection (e.g., treatment rested at room temperature). Therefore,
a new item asking about acceptance of time taken to prepare the
injection was added. In addition, CE ﬁndings from round 1
indicated that most of the patients (n ¼ 8 [89%]) associated the
frequency of dosing with the need to “remember” to take their
dose. Therefore, an additional item assessing how easy or
difﬁcult it was for patients to remember to take the injection
treatment was added for testing in round 2.
Some patients felt that the ﬁnal “overall acceptance” item was
repetitious. Therefore, an alternative version of the item was
included for testing in round 2, which used revised wording to
enhance clarity.
Revisions after round 2 interviews with patients using the PFP
(n ¼ 10)
Overall, the updated version of the 22-item I-TAQ was well
understood by patients and reported to be relevant in round 2
interviews (n ¼ 10). Low relevance was reported for perceived
efﬁcacy of the treatment because most of the patients did not
Fig. 2. – Overview of changes made to the I-TAQ after each round of interviews. I-TAQ, Injection-Treatment Acceptance
Questionnaire. (Color version of ﬁgure available online).
Fig. 1. – Final conceptual framework for the Injection-Treatment Acceptance Questionnaire (I-TAQ).
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substantially inﬂuence treatment acceptance, however, both
items were retained.
Furthermore, the new items capturing self-efﬁcacy, prepara-
tion time, and remembering to take the treatment were under-
stood and relevant to all 10 patients and were therefore retained.
The item asking speciﬁcally about injection site reactions was
merged with the general side effects item because patients did
not appear to interpret a conceptual distinction between the two
concepts.
Both the original and revised overall acceptance items were
well understood in round 2, although patients preferred the
newly added item wording overall. Therefore, the new item was
retained and the original overall acceptance item deleted.
Although not frequently experienced, pain was reported by
two patients in CE and was acknowledged to be a concept that
may signiﬁcantly affect treatment acceptance. Therefore, two
items assessing pain were added to form the 22-item I-TAQ and
were tested in round 3. The ﬁrst pain item asked about the
presence of pain when injecting, using a dichotomous “yes or no”
response option, whereas the second item captured acceptance
of pain. A skip pattern was used so that only those patients who
experienced pain reported acceptance.Revisions after round 3 interviews with patients using the PFS
(n ¼ 10)
Overall, the 22-item I-TAQ tested in round 3 was well understood
and all concepts were reported to be relevant to the 10 patients
using the PFS, with no new concepts reported to be missing.
Therefore, all items were retained and no new items added,
forming the ﬁnal 22-item I-TAQ ready for psychometric evalua-
tion (Fig. 2).Discussion
As new therapies requiring injections are introduced for CV
disease management, it is important to understand the patients’
perspectives of the treatment [6–8]. Because new treatments in
development, such as alirocumab [6–8], require subcutaneous
injection rather than orally consumed pills, it is important to
assess how acceptable patients ﬁnd this mode of administration
and their willingness to self-inject. To measure acceptance of the
subcutaneous treatment, a new PRO was needed, the initial
development and content validity testing of which is presented
in this article. Three rounds of successive qualitative interviews
with interim analysis informed revisions to the I-TAQ, resulting
in the development of a treatment acceptance measure with
strong content validity, appropriate for use with both patients
administering the treatment via a PFP and/or a PFS (Fig. 2).
Performing combined CE and CD in the same interview facilitated
an iterative approach to the reﬁnement of the instrument con-
tent. Although less commonly used than an approach whereby
pure CE interviews are followed by pure CD interviews [24–26],
this approach facilitates early testing of items and more rapid
instrument revision without sacriﬁcing the opportunity to intro-
duce new items and concepts into the tool.
The constructs of the Health Belief Model [12] provided a useful
framework for the development of the I-TAQ. Perceived efﬁcacy of
the treatment, self-efﬁcacy, side effects, injection convenience,
and overall acceptance were identiﬁed as domains of importance
in relation to treatment acceptance, with pain being a less
commonly relevant concept. Nevertheless, because it is important
to capture the presence or absence of pain in a self-injected
population, a question was added to the I-TAQ to understand
the pain associated with the injection [15,16]. Notably, where theimpact of treatment satisfaction/acceptance on adherence has
been reported in the literature [27,28] (supported by the Health
Belief Model [12]), the presence of pain was deemed a concept that
may negatively affect acceptance and therefore adherence and so
was deemed a key concept to capture in an injection population.
Although no bothersome side effects or effects on physical
functioning/daily activities were reported in this population, it
was deemed important to capture the absence of these effects. In
addition, it is known from the literature that such effects are
relevant concepts of treatment satisfaction/acceptance to capture
and may well be relevant in other patient populations receiving
treatment via subcutaneous injection.
The TSQM and the SATMED-Q are widely used measures of
treatment satisfaction in the literature [29–32]. Although there is
overlap in the concepts assessed by these measures and those
captured in the I-TAQ (e.g., perceived efﬁcacy, side effects, and
convenience), these generic measures are not conceptually com-
prehensive for injection-treatment populations. In addition,
although the SIAQ is speciﬁc to satisfaction with injection treat-
ments, the questions are phrased to ask about satisfaction with
injections in general, rather than asking speciﬁcally about a
particular treatment the patient is currently taking. Furthermore,
the SIAQ uses a “pre” and “post” injection recall period, whereas
an instrument with the option of being administered only once in
a study would provide greater ﬂexibility of use as it could be
included in both cross-sectional and longitudinal studies. More-
over, although the ACCEPT is a measure of treatment acceptance,
it is not speciﬁc to injectable treatments and includes items
measuring acceptance of oral medications. Therefore, the I-TAQ
is a new instrument with appropriate content validity for use
with patients who self-administer injection treatments that
overcomes the limitations of these other measures.
In addition, the study explored the relevance of treatment
acceptance in patients who self-administer their treatment via
subcutaneous injection. Findings from this qualitative study
support treatment acceptance as a more relevant concept for
this population, with more patients voicing a preference for the
term acceptance as opposed to satisfaction when describing their
treatment experience.
Study Limitations
All patients were recruited from a randomized controlled trial
and as a result had experience of using the injection treatment.
Although this can be of substantial value in terms of gaining
insight into relevant concepts relating to long-term use, transient
concerns before patients initiated therapy may have not been
accurately recalled and captured during interviews. In addition,
because of the lack of diversity in ethnicity, there is a lack of
evidence to support the generalizability of the I-TAQ in a non-
Caucasian population. Therefore, there could be value in assess-
ing the content validity of the measure in other cultures to
conﬁrm cross-cultural validity.
Although saturation was achieved for the whole sample, only
10 patients using the PFS were interviewed. Therefore, there may
be value in interviewing a larger sample of patients who use the
PFS to conﬁrm that no additional concepts are missing from the
questionnaire. Finally, the content validity of the I-TAQ has been
documented for use in high CV risk populations, therefore,
assessment of conceptual comprehensiveness in other self-
administered injection populations (e.g., diabetes) would be
required for wider use.
Future Research
A PRO was successfully developed to measure patients’ perspec-
tives of using self-administered, subcutaneous injections as a
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 0 0 – 1 0 0 7 1007therapeutic strategy. The next step is to psychometrically vali-
date the I-TAQ to establish its reliability and validity, as well as
the appropriateness of the hypothesized conceptual framework
and inform development of scoring, with possible item reduction.
Ideally, the responsiveness and predictive validity for long-term
adherence would also be established. Following psychometric
validation, the expectation is that the I-TAQ might form a reliable
and valid instrument with which to quantify the acceptability of
injection treatments in different disease populations.Conclusions
The I-TAQ is a treatment acceptance measure designed for use
with patients who self-administer their treatment via subcuta-
neous injection. Drafted by drawing on insights from existing
validated instruments, the I-TAQ has demonstrated strong con-
tent validity in injection-treatment samples through successive
rounds of qualitative interviews, with interim results informing
revisions iteratively. The next step is to psychometrically validate
the I-TAQ in a larger injection population to develop a scoring
algorithm and evaluate psychometric properties.Acknowledgments
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